NCT04106297View on ClinicalTrials.gov

A Study to Evaluate the Effects of Single and Multiple Oral Doses of GLPG3970

PHASE1CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

September 10, 2019

Primary Completion Date

March 5, 2021

Study Completion Date

March 5, 2021

Conditions
HealthyPsoriasis
Interventions
DRUG

GLPG3970 oral solution

GLPG3970 for oral administration

DRUG

Placebo oral solution

Placebo for oral administration

DRUG

GLPG3970 capsule

GLPG3970 for oral administration

Trial Locations (3)

2060

SGS Belgium NV - Clinical Pharmacology Unit Antwerp, Antwerp

MD2025

Clinical Republican Hospital Arensia Experimental Medicine, Chisinau

01135

ARENSIA Exploratory Medicine Unit, Kyiv

Sponsors

Lead Sponsor

Galapagos NV
All Listed Sponsors
lead

Galapagos NV

INDUSTRY